The 21-gene assay Oncotype DX has a great potential to guide decisions about initiating adjuvant chemotherapy in women with early-stage breast cancer. However, the benefit of Oncotype DX routine use in clinical practice remains questionable because of the assay's high cost and insufficient clinical utility evidence. In this talk, Natalia R. Kunst will present a comprehensive value of information analysis to assess the state of the evidence and quantify uncertainty on the use of 21-gene assay Oncotype DX, providing timely guidance on pressing clinical questions.
Natalia R. Kunst is a PhD Candidate at the University of Oslo and a Visiting PhD Candidate at the Yale School of Medicine. Kunst takes her PhD in Health Decision Science and focuses on the use of real-world evidence in medical decision-making by applying mathematical and statistical modeling.